Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 12, 2003. The report details specific corporate actions regarding share re-purchases and changes in director share interests, rather than providing comprehensive financial results for a fiscal period.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. The only financial figures disclosed relate to specific share transactions:
- Share Re-purchase Price: 1,252.58 pence per share.
- Director Share Purchase Price: £12.5968 per share.
Material Changes and Corporate Actions
The filing reports two material events occurring in early June 2003:
- Share Re-purchase: On June 11, 2003, the company purchased 1,190,000 Ordinary 25 pence shares for cancellation. This action was executed under authority granted by shareholders at the Annual General Meeting on May 19, 2003.
- Director Share Interest: On June 10, 2003, Director Mr. J.D. Coombe acquired 20 Ordinary Shares through the Company's ShareReward Plan. This included 10 shares via personal contribution and 10 shares via company matching contribution.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, future guidance, outlook, risk factors, or contingencies. The document is strictly a notification of the aforementioned share transactions.
Key Facts for Investor Verification
- Verify the total number of shares repurchased for cancellation (1,190,000) and the specific execution date (June 11, 2003).
- Confirm the price paid per share in the re-purchase (1,252.58 pence) against market prices on the transaction date.
- Note that this filing does not contain quarterly or annual financial performance data.